122 related articles for article (PubMed ID: 2120233)
1. Mutational and immunochemical analysis of plasminogen activator inhibitor 1.
Shubeita HE; Cottey TL; Franke AE; Gerard RD
J Biol Chem; 1990 Oct; 265(30):18379-85. PubMed ID: 2120233
[TBL] [Abstract][Full Text] [Related]
2. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center.
Sherman PM; Lawrence DA; Yang AY; Vandenberg ET; Paielli D; Olson ST; Shore JD; Ginsburg D
J Biol Chem; 1992 Apr; 267(11):7588-95. PubMed ID: 1559996
[TBL] [Abstract][Full Text] [Related]
3. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.
Sherman PM; Lawrence DA; Verhamme IM; Paielli D; Shore JD; Ginsburg D
J Biol Chem; 1995 Apr; 270(16):9301-6. PubMed ID: 7721851
[TBL] [Abstract][Full Text] [Related]
4. Sequence requirements in the reactive-center loop of plasminogen-activator inhibitor-1 for recognition of plasminogen activators.
Tucker HM; Gerard RD
Eur J Biochem; 1996 Apr; 237(1):180-7. PubMed ID: 8620872
[TBL] [Abstract][Full Text] [Related]
5. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
[TBL] [Abstract][Full Text] [Related]
6. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition.
Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
J Biol Chem; 1994 Nov; 269(44):27657-62. PubMed ID: 7961684
[TBL] [Abstract][Full Text] [Related]
7. Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator.
van Meijer M; Roelofs Y; Neels J; Horrevoets AJ; van Zonneveld AJ; Pannekoek H
J Biol Chem; 1996 Mar; 271(13):7423-8. PubMed ID: 8631768
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor I.
York JD; Li P; Gardell SJ
J Biol Chem; 1991 May; 266(13):8495-500. PubMed ID: 2022663
[TBL] [Abstract][Full Text] [Related]
9. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
Audenaert AM; Knockaert I; Collen D; Declerck PJ
J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
[TBL] [Abstract][Full Text] [Related]
10. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
[TBL] [Abstract][Full Text] [Related]
11. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
Ehrlich HJ; Gebbink RK; Keijer J; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1990 Aug; 265(22):13029-35. PubMed ID: 1695900
[TBL] [Abstract][Full Text] [Related]
12. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism.
Shore JD; Day DE; Francis-Chmura AM; Verhamme I; Kvassman J; Lawrence DA; Ginsburg D
J Biol Chem; 1995 Mar; 270(10):5395-8. PubMed ID: 7890653
[TBL] [Abstract][Full Text] [Related]
13. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
Lawrence D; Strandberg L; Grundström T; Ny T
Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
[TBL] [Abstract][Full Text] [Related]
14. On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.
Lijnen HR; Van Hoef B; Collen D
J Biol Chem; 1991 Mar; 266(7):4041-4. PubMed ID: 1900284
[TBL] [Abstract][Full Text] [Related]
15. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
Biochemistry; 1994 Mar; 33(12):3643-8. PubMed ID: 8142362
[TBL] [Abstract][Full Text] [Related]
16. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1. The distance between P3 and P1' determined by donor-donor fluorescence energy transfer.
Aleshkov SB; Fa M; Karolin J; Strandberg L; Johansson LB; Wilczynska M; Ny T
J Biol Chem; 1996 Aug; 271(35):21231-8. PubMed ID: 8702896
[TBL] [Abstract][Full Text] [Related]
18. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
[TBL] [Abstract][Full Text] [Related]
19. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.
Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF; Bassel-Duby RS
Proc Natl Acad Sci U S A; 1990 May; 87(9):3530-3. PubMed ID: 2110366
[TBL] [Abstract][Full Text] [Related]
20. Mutagenesis of recombinant protein C inhibitor reactive site residues alters target proteinase specificity.
Phillips JE; Cooper ST; Potter EE; Church FC
J Biol Chem; 1994 Jun; 269(24):16696-700. PubMed ID: 8206990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
